TherapeuticsMD Inc. (TXMD)

5.68
0.03 0.44
NASDAQ : Health Technology
Prev Close 5.71
Open 5.69
Day Low/High 5.60 / 5.78
52 Wk Low/High 3.50 / 7.01
Volume 957.53K
Avg Volume 1.95M
Exchange NASDAQ
Shares Outstanding 216.40M
Market Cap 1.27B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For TX-001HR

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For TX-001HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the acceptance of the NDA for TX-001HR by the U.

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the Company will participate in the Cowen and Company 38th Annual Healthcare Conference on March 12, and the Oppenheimer...

TherapeuticsMD Announces Fourth Quarter And Full Year 2017 Financial Results

TherapeuticsMD Announces Fourth Quarter And Full Year 2017 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its fourth quarter and full-year financial results for 2017.

TherapeuticsMD To Host Fourth Quarter And Year End 2017 Financial Results Conference Call And Webcast On February 20

TherapeuticsMD To Host Fourth Quarter And Year End 2017 Financial Results Conference Call And Webcast On February 20

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss its fourth quarter and year end 2017 financial and business...

TherapeuticsMD Announces Presentation At 36th Annual J.P. Morgan Healthcare Conference On January 10

TherapeuticsMD Announces Presentation At 36th Annual J.P. Morgan Healthcare Conference On January 10

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will present at the 36th Annual J.

TherapeuticsMD Announces Submission Of New Drug Application For TX-001HR

TherapeuticsMD Announces Submission Of New Drug Application For TX-001HR

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, announced today that it has submitted the New Drug Application (NDA) for TX-001HR, the company's investigational bio-identical hormone therapy...

TherapeuticsMD Announces FDA Acceptance Of New Drug Application And Prescription Drug User Fee Act (PDUFA) Date For TX-004HR

TherapeuticsMD Announces FDA Acceptance Of New Drug Application And Prescription Drug User Fee Act (PDUFA) Date For TX-004HR

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced the acceptance of the New Drug Application (NDA) resubmission for TX-004HR, the company's investigational applicator-free...

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, announced today that it has resubmitted the New Drug Application (NDA) for TX-004HR, the company's investigational applicator-free estradiol...

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will participate in the Stifel 2017 Healthcare Conference on November 14, and the Jefferies 2017 London...

TherapeuticsMD Announces Third Quarter 2017 Financial Results

TherapeuticsMD Announces Third Quarter 2017 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended September 30, 2017.

TherapeuticsMD Announces Plan To Resubmit The New Drug Application For TX-004HR

TherapeuticsMD Announces Plan To Resubmit The New Drug Application For TX-004HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the Company's investigational applicator-free...

TherapeuticsMD is Now Oversold (TXMD)

TherapeuticsMD is Now Oversold (TXMD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TherapeuticsMD To Host TX-004HR Regulatory Update And Third Quarter Financial Results Conference Call And Webcast On November 6

TherapeuticsMD To Host TX-004HR Regulatory Update And Third Quarter Financial Results Conference Call And Webcast On November 6

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss a TX-004HR regulatory update and third quarter financial...

First Week Of TXMD June 2018 Options Trading

First Week Of TXMD June 2018 Options Trading

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the June 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TherapeuticsMD Announces Multiple Presentations Related To TX-004HR And TX-001HR At NAMS 2017

TherapeuticsMD Announces Multiple Presentations Related To TX-004HR And TX-001HR At NAMS 2017

TherapeuticsMD, Inc. (NYSE American:TXMD), an innovative women's healthcare company, today announced the schedule of nine presentations at NAMS 2017, the annual meeting of the North American Menopause Society, in...

TherapeuticsMD Announces Closing Of Common Stock Offering

TherapeuticsMD Announces Closing Of Common Stock Offering

TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the closing of its previously announced underwritten public offering of 12.

TherapeuticsMD Announces Pricing Of Common Stock Offering

TherapeuticsMD Announces Pricing Of Common Stock Offering

TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the pricing of an underwritten public offering of 12.

TherapeuticsMD Announces Public Offering Of 12.4 Million Shares Of Common Stock

TherapeuticsMD Announces Public Offering Of 12.4 Million Shares Of Common Stock

TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the launch of an underwritten public offering of 12.

TherapeuticsMD Announces Move To Nasdaq Global Select Market

TherapeuticsMD Announces Move To Nasdaq Global Select Market

TherapeuticsMD, Inc. (NYSE American:TXMD), an innovative women's healthcare company, today announced that it will voluntarily move its stock exchange listing to the Nasdaq Global Select Market from the NYSE American LLC.

First Week Of November 17th Options Trading For TherapeuticsMD (TXMD)

First Week Of November 17th Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD, Inc. saw new options become available this week, for the November 17th expiration.

TherapeuticsMD Announces Submission Of Additional Endometrial Safety Information To The New Drug Application For TX-004HR

TherapeuticsMD Announces Submission Of Additional Endometrial Safety Information To The New Drug Application For TX-004HR

TherapeuticsMD, Inc. (NYSE American: TXMD), an innovative women's healthcare company, today announced the submission of the additional endometrial safety information that was requested by the Food and Drug Administration...

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will participate in the Morgan Stanley 15 th Annual Global Healthcare Conference on September 11-13, and the...

First Week of TXMD October 20th Options Trading

First Week of TXMD October 20th Options Trading

Investors in TherapeuticsMD, Inc. saw new options begin trading this week, for the October 20th expiration.

TherapeuticsMD Announces Publication Of Manuscript On The Women's Health Initiative Observational Study Of Vaginal Estrogen Use In Postmenopausal Women

TherapeuticsMD Announces Publication Of Manuscript On The Women's Health Initiative Observational Study Of Vaginal Estrogen Use In Postmenopausal Women

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced the publication of the manuscript detailing results of the Women's Health Initiative Observational Study of vaginal estrogen...

TherapeuticsMD Provides TX-004HR Regulatory Update

TherapeuticsMD Provides TX-004HR Regulatory Update

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the company's investigational applicator-free...

TherapeuticsMD Announces Second Quarter 2017 Financial Results

TherapeuticsMD Announces Second Quarter 2017 Financial Results

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended June 30, 2017.

TheStreet Quant Rating: D (Sell)